Caroline Tillett's most recent trade in Kenvue Inc was a trade of 23,158 Restricted Stock Units done . Disclosure was reported to the exchange on Dec. 15, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Kenvue | Caroline Tillett | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2025 | 23,158 | 0 | - | - | Restricted Stock Units | |
| Kenvue | Caroline Tillett | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2025 | 23,158 | 68,037 | - | 0 | Common Stock | |
| Kenvue | Caroline Tillett | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.28 per share. | 15 Dec 2025 | 11,846 | 56,191 | - | 17.3 | 204,699 | Common Stock |
| Kenvue | Caroline Tillett | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2025 | 4,399 | 62,052 | - | 0 | Common Stock | |
| Kenvue | Caroline Tillett | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2025 | 4,399 | 4,399 | - | - | Restricted Stock Units | |
| Kenvue | Caroline Tillett | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2025 | 3,371 | 63,173 | - | 0 | Common Stock | |
| Kenvue | Caroline Tillett | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2025 | 3,371 | 6,740 | - | - | Restricted Stock Units | |
| Kenvue | Caroline Tillett | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2025 | 2,994 | 0 | - | - | Restricted Stock Units | |
| Kenvue | Caroline Tillett | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2025 | 2,994 | 59,185 | - | 0 | Common Stock | |
| Kenvue | Caroline Tillett | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.21 per share. | 15 Dec 2025 | 2,251 | 59,801 | - | 17.2 | 38,740 | Common Stock |
| Kenvue | Caroline Tillett | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.21 per share. | 15 Dec 2025 | 1,725 | 61,448 | - | 17.2 | 29,687 | Common Stock |
| Kenvue | Caroline Tillett | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.28 per share. | 15 Dec 2025 | 1,532 | 57,653 | - | 17.3 | 26,473 | Common Stock |
| Kenvue | Caroline Tillett | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2025 | 1,538 | 1,538 | - | - | Restricted Stock Units | |
| Kenvue | Caroline Tillett | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2025 | 1,538 | 45,667 | - | 0 | Common Stock | |
| Kenvue | Caroline Tillett | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.22 per share. | 01 Dec 2025 | 788 | 44,879 | - | 17.2 | 13,569 | Common Stock |
| Kenvue | Caroline Tillett | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 81,837 | 81,837 | - | - | Stock Options | |
| Kenvue | Caroline Tillett | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 9,807 | 9,807 | - | - | Restricted Stock Units | |
| Kenvue | Caroline Tillett | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2025 | 4,267 | 8,533 | - | - | Restricted Stock Units | |
| Kenvue | Caroline Tillett | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2025 | 4,267 | 45,657 | - | 0 | Common Stock | |
| Kenvue | Caroline Tillett | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 23.04 per share. | 05 Mar 2025 | 1,529 | 44,128 | - | 23.0 | 35,228 | Common Stock |
| Kenvue | Caroline Tillett | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 19,121 | 0 | - | - | Restricted Stock Units | |
| Kenvue | Caroline Tillett | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 19,121 | 47,625 | - | 0 | Common Stock | |
| Kenvue | Caroline Tillett | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 7,645 | 0 | - | - | Restricted Stock Units | |
| Kenvue | Caroline Tillett | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 7,645 | 31,123 | - | 0 | Common Stock | |
| Kenvue | Caroline Tillett | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.75 per share. | 13 Feb 2025 | 6,235 | 41,390 | - | 21.7 | 135,611 | Common Stock |
| Kenvue | Caroline Tillett | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 3,000 | 24,490 | - | 0 | Common Stock | |
| Kenvue | Caroline Tillett | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 3,000 | 2,994 | - | - | Restricted Stock Units | |
| Kenvue | Caroline Tillett | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.75 per share. | 13 Feb 2025 | 2,619 | 28,504 | - | 21.7 | 56,963 | Common Stock |
| Kenvue | Caroline Tillett | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.23 per share. | 13 Feb 2025 | 1,012 | 23,478 | - | 21.2 | 21,485 | Common Stock |
| Kenvue | Tillett Caroline | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2024 | 1,498 | 2,994 | - | - | Restricted Stock Units | |
| Kenvue | Tillett Caroline | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2024 | 1,498 | 22,257 | - | 0 | Common Stock | |
| Kenvue | Caroline Tillett | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.08 per share. | 01 Dec 2024 | 767 | 21,490 | - | 24.1 | 18,469 | Common Stock |
| Kenvue | Caroline Tillett | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2024 | 111,009 | 111,009 | - | - | Stock Options | |
| Kenvue | Caroline Tillett | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2024 | 12,340 | 12,340 | - | - | Restricted Stock Units | |
| Kenvue | Tillett Caroline | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2024 | 3,000 | 21,787 | - | 0 | Common Stock | |
| Kenvue | Caroline Tillett | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2024 | 3,000 | 5,994 | - | - | Restricted Stock Units | |
| Kenvue | Tillett Caroline | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.34 per share. | 13 Feb 2024 | 1,028 | 20,759 | - | 19.3 | 19,882 | Common Stock |
| Kenvue | Tillett Caroline | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2024 | 21,321 | 21,321 | - | 0 | Common Stock | |
| Kenvue | Caroline Tillett | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2024 | 21,321 | 0 | - | - | Restricted Stock Units | |
| Kenvue | Caroline Tillett | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.67 per share. | 08 Feb 2024 | 6,961 | 14,360 | - | 19.7 | 136,923 | Common Stock |
| Kenvue | Caroline Tillett | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2024 | 6,675 | 0 | - | - | Restricted Stock Units | |
| Kenvue | Caroline Tillett | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2024 | 6,675 | 21,035 | - | 0 | Common Stock | |
| Kenvue | Caroline Tillett | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.67 per share. | 08 Feb 2024 | 2,248 | 18,787 | - | 19.7 | 44,218 | Common Stock |
| Kenvue | Caroline Tillett | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Dec 2023 | 39,705 | 39,705 | - | - | Stock Options | |
| Kenvue | Tillett Caroline | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Dec 2023 | 4,324 | 4,324 | - | - | Restricted Stock Units | |
| Kenvue | Caroline Tillett | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Oct 2023 | 113,957 | 113,957 | - | - | Stock Options | |
| Kenvue | Caroline Tillett | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Aug 2023 | 75,541 | 75,541 | - | - | Stock Options | |
| Kenvue | Caroline Tillett | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Aug 2023 | 74,422 | 74,422 | - | - | Stock Options | |
| Kenvue | Caroline Tillett | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Aug 2023 | 73,348 | 73,348 | - | - | Stock Options | |
| Kenvue | Caroline Tillett | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Aug 2023 | 23,158 | 23,158 | - | - | Restricted Stock Units | |
| Kenvue | Caroline Tillett | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Aug 2023 | 21,321 | 21,321 | - | - | Restricted Stock Units | |
| Kenvue | Caroline Tillett | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Aug 2023 | 19,121 | 19,121 | - | - | Restricted Stock Units | |
| Kenvue | Caroline Tillett | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Aug 2023 | 8,994 | 8,994 | - | - | Restricted Stock Units | |
| Kenvue | Caroline Tillett | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Aug 2023 | 7,645 | 7,645 | - | - | Restricted Stock Units | |
| Kenvue | Caroline Tillett | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Aug 2023 | 6,675 | 6,675 | - | - | Restricted Stock Units |